FDA Approves First Single-Dose Generic Treatment for Influenza

The U.S. Food and Drug Administration approved the first generic version of baloxavir marboxil, a single-dose treatment for influenza. The medication is indicated for patients aged 5 years and older and can be used to treat acute uncomplicated influenza if symptoms appeared within 48 hours, as well as for influenza prevention after contact with an infected person. The approval came in preparation for the 2026–2027 flu season. According to the FDA, influenza alone causes millions of illnesses in the United States annually. The most common side effects include diarrhea, bronchitis, nausea, sinusitis, and headaches. The drug is contraindicated in patients with allergic reactions to baloxavir marboxil or its ingredients. Increased availability of generic drugs enhances market competition and makes treatment more affordable and accessible.